Emtricitabine Capsule
Brand names: Emtriva
Category: Anti-Infective
FDA status: To Be Discontinued · Last FDA update: Jun 17, 2026 · First posted: Jun 17, 2026 · 1 manufacturers, 1 listed presentations
As of Jun 17, 2026, the FDA lists Emtricitabine Capsule as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Emtriva, Capsule, 200 mg (NDC 61958-0601-1) NDC 61958-0601-1 |
Gilead Sciences, Inc. | Not specified | Product expected to be available until March 2027 |
Related medications in shortage
Other Anti-Infective medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Emtricitabine Capsule (FDA data as of Jun 17, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Emtricitabine Capsule. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/emtricitabine-capsule.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).